No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)


- mikozy scalp (trichophytosis, microsporia);

- skin and nail mycoses caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton violaceum, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum;

- onychomycosis;

- severe common dermatomycosis of the smooth skin of the trunk and extremities, requiring systemic treatment;

- candidiasis of the skin and mucous membranes.

Dosing regimen

The duration of the course of treatment and the dosage regimen is set individually and depends on the localization process and the severity of the disease.

Inside for adults the drug is prescribed 250 mg 1 time / day (after a meal).

At onychomycosis the duration of treatment is about 6-12 weeks. With onychomycosis of the hands and feet (except for the big toe), or in young patients, the duration of treatment may be less than 12 weeks. With an infection of the big toe, a course of treatment in 3 months is usually sufficient. In rare cases, with a slower growth rate of nails, it may require longer treatment - up to 6 months or more.

At dermatomycosis of the feet (interdigital, plantar or sock type) the duration of treatment is from 2 to 6 weeks; at ringworm - from 2 to 4 weeks; at ring torso - 4 weeks; at candidiasis of the skin and mucous membranes 2 to 4 weeks.

At mycosis of the scalp caused by microsporum canis The recommended duration of treatment is more than 4 weeks.

Children weighing from 20 to 40 kg the drug is prescribed in a dose of 125 mg (1/2 tab.) 1 time / day, with body weight more than 40 mg - 250 mg 1 time / day. Duration of treatment mycosis of the scalp is about 4 weeks. In cases where the pathogen is Microsporum canis, treatment may be longer.

Elderly patients the drug is prescribed in the same doses as adults.

At severe renal failure (CC <50 ml / min or serum creatinine content> 300 μmol / l), at renal dysfunction the dose should be reduced by 2 times, for adults - 125 mg 1 time / day.

Adverse Effects

Gastrointestinal: dyspepsia, loss of appetite, nausea, diarrhea, feeling of fullness in the stomach, abdominal pain, disturbances in taste, including their loss (recovery occurs within a few weeks after stopping treatment); very rarely - hepatobiliary disorders (cholestatic jaundice).

Musculoskeletal system: arthralgia, myalgia.

Hemic and lymphatic: agranulocytosis, thrombocytopenia, neutropenia.

Allergic reactions: urticaria, rash; very rarely, toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions, malignant exudative erythema (Stevens-Johnson syndrome).


- pregnancy;

- breastfeeding period;

- children's age up to 3 years and children weighing up to 20 kg;

- hypersensitivity to the drug.

WITH caution the drug should be used internally in renal and / or liver failure, alcoholism, inhibition of bone marrow hematopoiesis, tumors, metabolic diseases, occlusive vascular diseases of the extremities.

Pregnanacy and breastfeeding

Experience of using the drug Thermicon® during pregnancy is limited, so its use in pregnancy is contraindicated.

Terbinafine is excreted in breast milk, so if necessary, the appointment of the drug during lactation should decide on the termination of breastfeeding.

AT experimental studies the teratogenic effect of Terbinafine was not detected. To date, no malformations have been reported with the use of terbinafine.

Application for violations of the liver

WITH caution the drug should be administered orally and externally in liver failure.

Application for violations of kidney function

Patients with renal failure orally appoint 125 mg 1 time / day.

WITH caution should be prescribed the drug externally in renal failure

Use in children

Contraindicated: children under 3 years old and children weighing up to 20 kg.

Use in elderly patients

Elderly patients the drug is prescribed in the same doses as adults.

Special notes

It should be borne in mind that irregular use or early termination of treatment increases the risk of recurrence.

The duration of therapy may be determined by the presence of concomitant diseases, the condition of the nails at the beginning of the course of treatment.

If after 2 weeks of treatment with Thermicon there is no improvement in the condition, it is necessary to re-determine the causative agent and its sensitivity to the drug.

Systemic use in onychomycosis is justified only in the case of a total lesion of most nails, the presence of pronounced subungual hyperkeratosis, the ineffectiveness of the previous local therapy. In the treatment of onychomycosis, the clinical response is usually observed several months after mycological cure and discontinuation of the course of treatment, due to the rate of growth of a healthy nail. Removal of nail plates in the treatment of onychomycosis of the hands for 3 weeks and onychomycosis of the feet for 6 weeks is not required.

During treatment, liver serum transaminase activity should be monitored. In rare cases, after 3 months of treatment, cholestasis and hepatitis develop. If you identify symptoms of abnormal liver function (weakness, persistent nausea, lack of appetite, abdominal pain, jaundice, dark urine, or colorless feces), you must stop the drug.

With extreme caution, the drug should be prescribed to patients with psoriasis, since in very rare cases, terbinafine can provoke an exacerbation of psoriasis.

When treating the drug should follow the general rules of hygiene to prevent the possibility of re-infection through underwear and shoes. In the process (after 2 weeks) and at the end of treatment it is necessary to produce antifungal treatment of shoes, socks and stockings.

With the development of allergic reactions, the drug should be canceled.

Use in pediatrics

Thermikon® contraindicated in children under 3 years old and children weighing up to 20 kg.

Influence on ability to drive motor transport and control mechanisms

Terbinafine does not affect the ability to drive and perform work that requires high concentration of attention and speed of psychomotor reactions.


Symptoms: nausea, vomiting, pain in the lower abdomen and epigastric region, dizziness.

Treatment: gastric lavage followed by the appointment of Activated carbon and / or symptomatic therapy.

Drug interactions

Terbinafine inhibits CYP2D6 isoenzyme and slows down the metabolism of drugs such as tricyclic antidepressants and selective serotonin reuptake blockers (for example, desipramine, fluvoxamine), beta1-adrenergic blockers (metoprolol, propranolol), antiarrhythmic agents (flecainide, propafenone), MAO inhibitors of type B (for example, selegiline) and antipsychotic drugs (for example, chlorpromazine, haloperidol).

Inductors of isoenzymes of the cytochrome P450 system (for example, rifampicin) can accelerate the excretion of terbinafine from the body, inhibitors of isoenzymes of the cytochrome P450 system (for example, cimetidine) can slow it down.With simultaneous use with such drugs may require a dose adjustment of tebinafina.

With simultaneous use of terbinafine and oral contraceptives may be a violation of the menstrual cycle.

Terbinafine reduces caffeine clearance by 20% and increases its T1/2 on31%.

Terbinafine does not affect the clearance of antipyrine, Digoxin, Warfarin .

Ethanol and other hepatotoxic drugs, while used with a thermocon, increase the risk of developing hepatotoxicity.

Storage conditions

List B. The drug should be kept out of the reach of children, protected from light at a temperature not exceeding 25 ° C.

42 Items